Alnylam Pharmaceuticals (ALNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2012 | 12-2011 | 09-2011 | 06-2011 | 03-2011 | |
| Sales | 20,587 | 20,455 | 20,791 | 20,614 | 20,897 |
| Gross Profit | 20,587 | 20,455 | 20,791 | 20,614 | 20,897 |
| Operating Expenses | 31,480 | 34,041 | 33,229 | 33,732 | 36,573 |
| Operating Income | -10,893 | -13,586 | -12,438 | -13,118 | -15,676 |
| Other Income | -475 | -717 | -799 | -706 | -609 |
| Pre-tax Income | -11,368 | -14,303 | -13,237 | -13,824 | -16,285 |
| Net Income Continuous | -11,368 | -14,303 | -13,237 | -13,824 | -16,285 |
| Net Income | $-11,368 | $-14,303 | $-13,237 | $-13,824 | $-16,285 |
| EPS Basic Total Ops | -0.25 | -0.34 | -0.31 | -0.33 | -0.38 |
| EPS Basic Continuous Ops | -0.25 | -0.34 | -0.31 | -0.33 | -0.38 |
| EPS Diluted Total Ops | -0.25 | -0.34 | -0.31 | -0.33 | -0.38 |
| EPS Diluted Continuous Ops | -0.25 | -0.34 | -0.31 | -0.33 | -0.38 |
| EBITDA(a) | $-8,772 | $-12,349 | $-11,176 | $-11,831 | $-14,337 |